Humanigen Inc (HGENQ)

[Scooter McCabe]

The bigger problem is this the sample sizes and improvement achieved in the placebo group. From the article:

Clinical improvement, defined as improvement of at least 2 points on the 8-point ordinal clinical endpoints scale, was observed in 11 out of 12 (92%) lenzilumab treated patients and 22 out of 27 (81%) untreated patients.

So you had a smaller drug arm and a larger placebo group. In the larger group you saw 81% improvement without the drug. The numbers got played with here to favor the out come.

Also the disclosure states Mayo Clinic has a financial interest in the this drug.

Hopefully an actual study will get done with comparable placebo and drug arms. Mayo has come under fire in the past about stuff like this.

https://www.twincities.com/2011/12/25/u-mayo-cultivate-close-ties-to-drug-firms/